PubRank

C B Begg

Author PubWeight™ 103.84‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Racial differences in the treatment of early-stage lung cancer. N Engl J Med 1999 9.65
2 Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999 5.95
3 The influence of hospital volume on survival after resection for lung cancer. N Engl J Med 2001 4.83
4 Assessment of diagnostic tests when disease verification is subject to selection bias. Biometrics 1983 4.51
5 Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making 1985 4.47
6 Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 2001 3.65
7 Biases in the assessment of diagnostic tests. Stat Med 1987 3.48
8 Screening for cutaneous melanoma by skin self-examination. J Natl Cancer Inst 1996 3.23
9 Influence of hospital procedure volume on outcomes following surgery for colon cancer. JAMA 2000 3.18
10 The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev 2001 2.87
11 Who gets adjuvant treatment for stage II and III rectal cancer? Insight from surveillance, epidemiology, and end results--Medicare. J Clin Oncol 2001 2.43
12 A general regression methodology for ROC curve estimation. Med Decis Making 1988 2.37
13 A treatment allocation procedure for sequential clinical trials. Biometrics 1980 2.26
14 Role of video-assisted thoracic surgery in the treatment of pulmonary metastases: results of a prospective trial. Ann Thorac Surg 1996 1.91
15 Testing for fetal pulmonary maturity: ROC analysis involving covariates, verification bias, and combination testing. Med Decis Making 1990 1.68
16 Treatment allocation methods in clinical trials: a review. Stat Med 1985 1.67
17 The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125I implantation. Int J Radiat Oncol Biol Phys 1991 1.58
18 Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: results of a phase II study. Br J Urol 1997 1.55
19 Is Trichomonas vaginalis a cause of cervical neoplasia? Results from a combined analysis of 24 studies. Int J Epidemiol 1994 1.55
20 Construction of receiver operating characteristic curves when disease verification is subject to selection bias. Med Decis Making 1984 1.41
21 Diamond's correction method--a real gem or just cubic zirconium? Med Decis Making 1991 1.40
22 The association of patients' socioeconomic characteristics with the length of hospital stay and hospital charges within diagnosis-related groups. N Engl J Med 1988 1.34
23 Are the elderly predisposed to toxicity from cancer chemotherapy? An investigation using data from the Eastern Cooperative Oncology Group. Cancer Clin Trials 1980 1.32
24 Optimal sample size for a series of pilot trials of new agents. Biometrics 1996 1.28
25 The impact of treatment allocation procedures on nominal significance levels and bias. Control Clin Trials 1987 1.22
26 The use of ambulatory testing in prepaid and fee-for-service group practices. Relation to perceived profitability. N Engl J Med 1986 1.16
27 A measure to aid in the interpretation of published clinical trials. Stat Med 1985 1.15
28 Clinical trials and drug toxicity in the elderly. The experience of the Eastern Cooperative Oncology Group. Cancer 1983 1.14
29 Staging of malignant pleural mesothelioma: comparison of CT and MR imaging. AJR Am J Roentgenol 1999 1.14
30 High-dose ifosfamide with mesna uroprotection: a phase I study. J Clin Oncol 1990 1.09
31 Eligibility and extrapolation in cancer clinical trials. J Clin Oncol 1987 1.07
32 CT detection of retroperitoneal lymph node metastases in patients with clinical stage I testicular nonseminomatous germ cell cancer: assessment of size and distribution criteria. AJR Am J Roentgenol 1997 1.01
33 High peripheral blast count in adult acute myelogenous leukemia is a primary risk factor for CNS leukemia. J Clin Oncol 1988 1.00
34 Assessment of diagnostic technologies. Methodology for unbiased estimation from samples of selectively verified patients. Invest Radiol 1985 0.95
35 The effects of physicians' training and personality on test ordering for ambulatory patients. Am J Public Health 1984 0.94
36 Properties of a nonparametric test for early comparison of treatments in clinical trials in the presence of surrogate endpoints. Biometrics 1999 0.94
37 The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results. Urology 1997 0.93
38 Use of coagulation tests to predict the clinical progress of pre-eclampsia. Lancet 1976 0.91
39 Eastern Cooperative Oncology Group study of the cytochemistry of adult acute myeloid leukemia by correlation of subtypes with response and survival. Cancer Res 1981 0.90
40 Methodology for the differential diagnosis of a complex data set. A case study using data from routine CT scan examinations. Med Decis Making 1983 0.89
41 The effects of group size on test ordering for hypertensive patients. N Engl J Med 1983 0.89
42 Alcohol consumption and breast cancer. Lancet 1983 0.88
43 Comparison of adriamycin with cyclophosphamide in patients with advanced endometrial cancer. Cancer Treat Rep 1978 0.86
44 Cooperative groups and community hospitals. Measurement of impact in the community hospitals. Cancer 1983 0.86
45 A comparative clinical trial of adriamycin and 5-fluorouracil in advanced prostatic cancer: prognostic factors and response. Prostate 1983 0.85
46 Participation of community hospitals in clinical trials: analysis of five years of experience in the Eastern Cooperative Oncology Group. N Engl J Med 1982 0.85
47 Cancer, genes, and the environment. N Engl J Med 2000 0.84
48 Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 1984 0.83
49 Diverse prognosis in metastatic breast cancer: who should be offered alternative initial therapies? Breast Cancer Res Treat 1989 0.82
50 Cancer chemotherapy in the elderly. Semin Oncol 1989 0.82
51 Treatment allocation for nonlinear models in clinical trials: the logistic model. Biometrics 1984 0.81
52 A study of the use of the probability-of-being-in-response function as a summary of tumor response data. Biometrics 1982 0.81
53 Methodologic standards for diagnostic test assessment studies. J Gen Intern Med 1988 0.81
54 ROC curve regression analysis: the use of ordinal regression models for diagnostic test assessment. Environ Health Perspect 1994 0.81
55 Age and Hodgkin's disease: the impact of competing risks and possibly salvage therapy on long term survival: an E.C.O.G. study. Leuk Res 1993 0.80
56 Prolonged unmaintained remission after intensive consolidation therapy in adult acute nonlymphocytic leukemia. Cancer Treat Rep 1987 0.79
57 The influence of uninterpretability on the assessment of diagnostic tests. J Chronic Dis 1986 0.78
58 Randomized clinical trial comparing two dose regimens of ICRF-159 in refractory malignant lymphomas. Cancer Treat Rep 1980 0.78
59 Adult non-Hodgkin's lymphoma. Correlation of cell surface marker phenotype with prognosis, the new working formulation, and the Rappaport and Lukes-Collins histomorphologic schemes. Cancer 1983 0.78
60 A randomized study of the efficacy of consolidation therapy in adult acute nonlymphocytic leukemia. Blood 1984 0.78
61 A case-series study of p53 nuclear overexpression in early-stage stomach cancer. Ann N Y Acad Sci 1995 0.78
62 Patient-oriented performance measures of diagnostic tests. 2. Assignment potential and assignment strength. Med Decis Making 1984 0.77
63 Estimating the relative risk of developing melanoma in INK4A carriers. Eur J Cancer Prev 2004 0.77
64 Planning controlled clinical trials. Prostatic cancer. Urology 1997 0.77
65 Treatment of renal carcinoma: a phase III randomized trial of oral medroxyprogesterone (Provera), hydroxyurea, and nafoxidine. Cancer Treat Rep 1981 0.75
66 Timing of radiotherapy in the treatment of early-stage breast cancer. J Clin Oncol 1993 0.75
67 VM-26, a new anticancer drug with effectiveness in malignant lymphoma: an Eastern Cooperative Oncology Group Study (EST 1474). Cancer Treat Rep 1979 0.75
68 Patient-oriented performance measures of diagnostic tests. 1. Tools for prospective evaluation of test order decisions. Med Decis Making 1984 0.75
69 Marrow transplantation for acute nonlymphoblastic leukemia. N Engl J Med 1980 0.75
70 Response to ROC steady. Med Decis Making 1988 0.75
71 Cancer clinical trials in the USA: patient eligibility, generalizability of results and technology transfer. Bull Cancer 1987 0.75
72 Surface marker identification of small cleaved follicular center cell lymphomas with a highly favorable prognosis. Cancer Res 1982 0.75
73 A critical comparison of allogeneic bone marrow transplantation and conventional chemotherapy as treatment for acute nonlymphocytic leukemia. J Clin Oncol 1984 0.75
74 Quality of cancer clinical trials. Ann Oncol 1990 0.75
75 Risk factor analysis of screening data. J Chronic Dis 1987 0.75
76 Phase II study of vinblastine-CCNU, triazinate, and dactinomycin in advanced renal cell cancer. Cancer Treat Rep 1981 0.75
77 Patient-oriented performance measures of diagnostic tests. 3. U-Factor. Med Decis Making 1984 0.75
78 Evaluation of efficient designs for observational epidemiologic studies. Biometrics 1987 0.75
79 Estimation of risks when verification of disease status is obtained in a selected group of subjects. Am J Epidemiol 1984 0.75
80 The participation of community hospitals in cancer clinical trials: results and impact of the Eastern Cooperative Oncology Group Program. Prog Clin Biol Res 1983 0.75